atorvastatin has been researched along with tacrolimus in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (25.00) | 29.6817 |
| 2010's | 8 (50.00) | 24.3611 |
| 2020's | 4 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Asberg, A; Hermann, M; Holdaas, H; Lemahieu, WP; Maes, BD; Vanrenterghem, Y; Verbeke, K | 1 |
| Abramowicz, D; Berkenboom, G; Broeders, N; Carpentier, Y; Ghisdal, L; Unger, P; Wissing, KM | 1 |
| Hoskova, L; Kautzner, J; Kubanek, M; Malek, I; Podzimkova, M; Skalicka, B; Vymetalova, Y | 1 |
| Amundsen, R; Asberg, A; Christensen, H; Zabihyan, B | 1 |
| Haron, MM; Houssen, ME; Ibrahim, TM; Metwally, SS | 1 |
| Brunet, M; Cofán, F; Cofán, M; Guillén, D; Millán, O; Ros, E | 1 |
| Corcione, N; Di Pace, AL; Ferraro, P; Giordano, A; Monaco, M; Nappo, G; Polimeno, M; Romano, MF; Romano, S; Sorrentino, A | 1 |
| Burger, D; Maliepaard, M; Neef, C; Teerenstra, S; Yu, Y | 1 |
| Ahn, KW; Atallah, E; Boyd, J; Bunner, P; Carlson, KS; Craig, M; Cumpston, A; D'Souza, A; Drobyski, W; Fenske, TS; Guru Murthy, GS; Hamadani, M; Hari, PN; Horowitz, MM; Kanate, AS; Michaelis, L; Pasquini, MC; Rizzo, JD; Saber, W; Visotcky, A | 1 |
| Asal, NJ; Migliozzi, DR | 1 |
| Bašić-Jukić, N; Sabljić, Z | 1 |
| Harabayashi, R; Nagayama, K; Nakamura, Y; Sugimoto, T; Takahashi, K; Takahashi, M; Uchida, J | 1 |
3 review(s) available for atorvastatin and tacrolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
Clinical Controversy in Transplantation: Tacrolimus Versus Cyclosporine in Statin Drug Interactions.
Topics: Adult; Atorvastatin; Cyclosporine; Cytochrome P-450 CYP3A; Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Liver-Specific Organic Anion Transporter 1; Organ Transplantation; Simvastatin; Tacrolimus | 2020 |
4 trial(s) available for atorvastatin and tacrolimus
| Article | Year |
|---|---|
Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus.
Topics: Area Under Curve; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcineurin Inhibitors; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Synergism; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Indoles; Lactones; Liver; Liver-Specific Organic Anion Transporter 1; Male; Organic Anion Transporters; Pravastatin; Pyrroles; Simvastatin; Tacrolimus; Time Factors | 2005 |
Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation.
Topics: Adult; Apolipoproteins; Atorvastatin; Body Mass Index; Creatinine; Cross-Over Studies; Drug Therapy, Combination; Endothelium, Vascular; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunosuppressive Agents; Kidney Transplantation; Lipids; Male; Middle Aged; Pyrroles; Tacrolimus; Triglycerides | 2006 |
Biomarker assessment of the immunomodulator effect of atorvastatin in stable renal transplant recipients and hypercholesterolemic patients.
Topics: Adenosine Triphosphate; Adult; Aged; Atorvastatin; Biomarkers; Cell Proliferation; Culture Media, Conditioned; Cytokines; Female; Gene Expression Regulation; Heptanoic Acids; Humans; Hypercholesterolemia; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Mycophenolic Acid; Pyrroles; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Tacrolimus; Transplantation | 2010 |
Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation.
Topics: Adult; Aged; Allografts; Atorvastatin; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Male; Methotrexate; Middle Aged; Prospective Studies; Survival Rate; Tacrolimus | 2017 |
9 other study(ies) available for atorvastatin and tacrolimus
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cohort Studies; Cyclosporine; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heart Transplantation; Heptanoic Acids; Humans; Immunosuppressive Agents; Indoles; Male; Middle Aged; Prospective Studies; Pyrroles; Tacrolimus; Treatment Outcome; Triglycerides | 2009 |
Cyclosporine A, but not tacrolimus, shows relevant inhibition of organic anion-transporting protein 1B1-mediated transport of atorvastatin.
Topics: Atorvastatin; Cell Line; Cyclosporine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Organic Anion Transporters; Pyrroles; Tacrolimus | 2010 |
Effects of immunomodulatory drugs on plasma inflammatory markers in a rabbit model of atherosclerosis.
Topics: Animals; Atherosclerosis; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol; Cholesterol, Dietary; Cholesterol, HDL; Cholesterol, LDL; Cyclosporine; Heptanoic Acids; Immunologic Factors; Inflammation; Interferon-gamma; Interleukin-6; Male; Plasma; Pyrroles; Rabbits; Tacrolimus; Triglycerides | 2011 |
Differential effect of atorvastatin and tacrolimus on proliferation of vascular smooth muscle and endothelial cells.
Topics: Aged; Aged, 80 and over; Antigens, CD; Atorvastatin; beta Catenin; Cardiovascular Agents; Cell Proliferation; Cells, Cultured; Cyclin B; DNA Replication; Dose-Response Relationship, Drug; Drug-Eluting Stents; Endoglin; Heptanoic Acids; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Phosphorylation; Pyrroles; Receptors, Cell Surface; Tacrolimus; Time Factors | 2012 |
Investigation into the interchangeability of generic formulations using immunosuppressants and a broad selection of medicines.
Topics: Anilides; Area Under Curve; Atorvastatin; Benzodiazepines; Chemistry, Pharmaceutical; Cyclosporine; Drugs, Generic; Humans; Immunosuppressive Agents; Mycophenolic Acid; Nitriles; Olanzapine; Perindopril; Piperidines; Tacrolimus; Therapeutic Equivalency; Tosyl Compounds; Tryptamines; Venlafaxine Hydrochloride | 2015 |
Toxic myopathy and liver damage caused by concomitant therapy with remdesivir, atorvastatin, ezetimibe, and tacrolimus in a renal transplant patient with recently treated SARS-CoV-2 induced pneumonia: A case report.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Atorvastatin; COVID-19 Drug Treatment; Ezetimibe; Humans; Kidney Transplantation; Liver; Myotoxicity; Pneumonia; SARS-CoV-2; Tacrolimus | 2022 |
Safety Profile of the Concomitant Use of Atorvastatin and Cyclosporine in Renal Transplant Recipients.
Topics: Atorvastatin; Cyclosporine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Kidney Transplantation; Retrospective Studies; Tacrolimus | 2023 |